Welcome to our dedicated page for Microbot Medical news (Ticker: $MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Microbot Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Microbot Medical's position in the market.
News
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) successfully completed the Electromagnetic Compatibility (EMC) testing section of the Verification and Validation (V&V) process for its LIBERTY Robotic Surgical System. This achievement is a crucial step towards the company's regulatory submission and the FDA's approval for clinical trials. The V&V process ensures that the product aligns with specified requirements and serves its intended purpose, highlighting Microbot's commitment to quality and safety standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) announced the granting of the 'One & Done®' trademark from the US Patent and Trademark Office for its LIBERTY Robotic Surgical System, highlighting its unique feature of integrating guidewires, microcatheters, and other instruments for endovascular procedures. This move expands the company's proprietary assets and sets its product apart in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
-
Rhea-AI Summary
Microbot Medical Inc. announces 100% success rate in reaching targets with no adverse events in pre-clinical study using the LIBERTY Robotic Surgical System. The study involved 48 animal targets and visual examination after 72 hours showed no evidence of vascular injury or adverse events. 6 LIBERTY Systems were used, all performing flawlessly with 100% usability and technical success. The company plans to submit an IDE application to the FDA for a pivotal clinical trial in humans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
Rhea-AI Summary
Microbot Medical Inc. has received confirmation for the commencement of the process to support its future CE Mark approval for the LIBERTY® Robotic Surgical System in Europe. The Company will conduct audits for ISO 13485 certification during the first half of 2024 to ensure compliance with EU Medical Devices Regulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Microbot Medical Inc. announces dismissal of counterclaim in legal action
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.53%
Tags
-
Rhea-AI Summary
Microbot Medical Inc. announces successful outcomes of pivotal pre-clinical study for LIBERTY Robotic Surgical System
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.96%
Tags
Rhea-AI Summary
Microbot Medical partners with a Contract Research Organization (CRO) in the US to support its upcoming clinical trial for the LIBERTY® Robotic Surgical System. The CRO will provide research management services and guidance throughout the trial process, enhancing Microbot's capabilities. This engagement is expected to help the company achieve necessary compliances with the FDA and navigate the regulatory landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
-
Rhea-AI Summary
Microbot Medical Inc. announces growing global recognition of its LIBERTY® Robotic Surgical System
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
-
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) has signed a manufacturing agreement with B.Y. Medimor Ltd. for the production of its LIBERTY® Robotic Surgical System, marking a significant step towards expected first in human clinical trials and subsequent commercialization. The agreement covers the manufacturing of the system for the clinical trial and the initial systems for commercialization, reinforcing the company's transition from research and development to the clinical and commercial stage in the field of endovascular robotics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
Microbot Medical, Inc.
Nasdaq:MBOT
MBOT Rankings
MBOT Stock Data
13.66M
14.15M
1.68%
12.21%
1.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
HINGHAM
About MBOT
microbot medical was founded with the vision of pioneering micro invasive surgery, transforming one of the biggest trends in healthcare - minimally invasive surgery (estimated to be close to $20b by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. through its unique platforms, microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. microbot’s virob platform is an autonomous advancing micro robot (aamr), less then 1mm in diameter, which has the ability to advance (forward/bac